Clinical trial
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice…
NCT00487058 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00487058 |
|---|---|
| Title | A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors |
| Official title | A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors. |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | Gimatecan |
| Enrollment | 28 |
| Start date | May 1, 2007 |
| Primary completion | Jun 1, 2008 |
| First posted | Jun 15, 2007 |
| Last update posted | Nov 19, 2009 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: